Optimizing use of basiliximab in liver transplantation

Optimizing use of basiliximab in liver transplantation

Carlo B Ramirez, Adam Bozdin, Adam Frank, Warren Maley, Cataldo DoriaDepartment of Surgery, Thomas Jefferson University, Philadelphia, PA, USAAbstract: Antibody induction therapy has not been part of standard immunosuppressive regimens in liver transplantation. However, in recent years there has bee...

Full description

Bibliographic Details
Main Authors:	Carlo B Ramirez, Adam Bozdin, Adam Frank, et al
Format:	Article
Language:	English
Published:	Dove Medical Press 2010-01-01
Series:	Transplant Research and Risk Management
Online Access:	http://www.dovepress.com/optimizing-use-of-basiliximab-in-liver-transplantation-a3893

Similar Items

The role of basiliximab in renal function after liver transplantation
by: Mikel Gastaca, MD
Published: (2022-03-01)

Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study
by: Mohamed Hashim, et al.
Published: (2020-09-01)

The role of basiliximab in the evolving renal transplantation immunosuppression protocol
by: Paola Salis, et al.
Published: (2008-06-01)

Fatal anaphylactic reaction due to Basiliximab
by: Patricia Lovisolo, et al.
Published: (2017-04-01)

Basiliximab for early perioperative transplant-associated thrombotic microangiopathy after lung transplantation: a case report
by: Naohiro Ijiri, et al.
Published: (2022-09-01)

Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience
by: Masashi Furukawa, et al.
Published: (2022-06-01)

Comparative Study of the Cellular Pharmacodynamics of Tacrolimus in Renal Transplant Recipients Treated with and without Basiliximab
by: Kentaro Sugiyama Ph.D., et al.
Published: (2012-03-01)

IL-2 Receptor Antagonist (Basiliximab) Is Associated with Rapid Fibrosis Progression in Patients with Recurrent Hepatitis C after Liver Transplantation
by: Ibrahim A. Hanouneh, et al.
Published: (2010-01-01)

Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation
by: Himanshu V Patel, et al.
Published: (2014-01-01)

Reply to: “correspondence about “Efficacy and safety of basiliximab”
by: Mohamed Hashim, et al.
Published: (2022-03-01)

Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin
by: Rachel Jeong, et al.
Published: (2020-10-01)

Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome
by: Sailaja Kesiraju, et al.
Published: (2014-01-01)

EXPERIÊNCIA COM USO DE BASILIXIMAB (SIMULECT®) EM UM ÚNICO SERVIÇO DE TRANSPLANTE RENAL
by: Tereza Matuck, et al.
Published: (2005-01-01)

Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
by: Martina Koch, et al.
Published: (2009-01-01)

Comparison of Basiliximab and Anti‐Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis
by: David Ansari, et al.
Published: (2016-01-01)

In response to: Benefit of neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction.
by: Knight, SR, et al.
Published: (2008)

Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review
by: Bruno Mendes, et al.
Published: (2022-08-01)

The comparative efficacy and safety of basiliximab and antithymocyte globulin in deceased donor kidney transplantation: a multicenter cohort study
by: Su Yeon Hong, et al.
Published: (2023-01-01)

Clinical Correlates and Outcomes of Dual Basiliximab and Antithymocyte Globulin Induction in Kidney Transplant Recipients: A National Study
by: Ngan N. Lam, MD, et al.
Published: (2021-08-01)

Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
by: Haynes, R, et al.
Published: (2014)

Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
by: Haynes, R, et al.
Published: (2014)

Reduced Progression of Cardiac Allograft Vasculopathy with Routine Use of Induction Therapy with Basiliximab
by: Ricardo Wang, et al.
Published: (2015-01-01)

Low dose thymoglobulin versus basiliximab in cytomegalovirus positive kidney transplant recipients: Effectiveness of preemptive cytomegalovirus modified strategy
by: Camilo Montero, et al.
Published: (2023-03-01)

Antithymocyte globulin versus basiliximab induction for kidney transplantation in elderly patients: matched analysis within the Korean multicentric registry
by: Jun Young Lee, et al.
Published: (2022-09-01)

Basiliximab for the therapy of acute T cell–mediated rejection in kidney transplant recipient with BK virus infection: A case report
by: Tingting Chen, et al.
Published: (2022-09-01)

Basiliximab impairs regulatory T cell (TREG) function and could affect the short-term graft acceptance in children with heart transplantation
by: Jacobo López-Abente, et al.
Published: (2021-01-01)

POS-744 CLINICAL CORRELATES AND OUTCOMES OF DUAL BASILIXIMAB AND THYMOGLOBULIN INDUCTION IN KIDNEY TRANSPLANT RECIPIENTS: A NATIONAL STUDY
by: N. Lam N, et al.
Published: (2021-04-01)

Low dose thymoglobulin versus basiliximab in cytomegalovirus positive kidney transplant recipients: Effectiveness of preemptive cytomegalovirus modified strategy
by: Camilo Montero, et al.
Published: (2023-03-01)

Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
by: Sang Jin Kim, et al.
Published: (2020-05-01)

Early monitoring of the human polyomavirus BK replication and sequencing analysis in a cohort of adult kidney transplant patients treated with basiliximab
by: Mischitelli Monica, et al.
Published: (2011-08-01)

Anti-interleukin-2 receptor antibodies&mdash;basiliximab and daclizumab&mdash;for the prevention of acute rejection in renal transplantation
by: Junichiro Sageshima, et al.
Published: (2009-06-01)

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
by: Haynes, R, et al.
Published: (2014)

Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia
by: Zhenli Huang, et al.
Published: (2022-11-01)

Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial
by: Aziza Ajlan, et al.
Published: (2021-06-01)

P1292: BASILIXIMAB MAY BE THE POTENTIAL SOLUTION FOR SEVERE LIVER CHRONIC GRAFT-VERSUS-HOST DISEASE: A PROSPECTIVE PILOT STUDY
by: Dao-Xing Deng, et al.
Published: (2023-08-01)

Impact of Induction Immunosuppressants on T Lymphocyte Subsets after Kidney Transplantation: A Prospective Observational Study with Focus on Anti-Thymocyte Globulin and Basiliximab Induction Therapies
by: Hyung Duk Kim, et al.
Published: (2023-09-01)

Treating a GAD65 antibody-associated limbic encephalitis with Basiliximab, a case study
by: Guido eWidman, et al.
Published: (2015-08-01)

Outcomes of thymoglobulin versus basiliximab induction therapies in living donor kidney transplant recipients with mild to moderate immunological risk – a retrospective analysis of UNOS database
by: Hatem Ali, et al.
Published: (2023-12-01)

Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report
by: Maiah Zarrabi, et al.
Published: (2023-05-01)

Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death.
by: Plata-Munoz, J, et al.
Published: (2009)